Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.28.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:59:05.022Z. Historical observations retain their original dates. Historical series through 2019-07-31.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
-0.84
EARNINGS PER SHARE (EPS) AVG 3Y
-0.70
EARNINGS PER SHARE (EPS) AVG 5Y
-0.68
EARNINGS PER SHARE (EPS) AVG 10Y
-0.57
EARNINGS PER SHARE (EPS) AVG 15Y
-0.47
EARNINGS PER SHARE (EPS) AVG 20Y
-0.46
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Summit Therapeutics Inc.
Market Cap
$13.74B
Earnings Per Share (EPS)
N/A
TTM Avg
-0.84
3Y Avg
-0.70
5Y Avg
-0.68
Market Cap
$14.04B
Earnings Per Share (EPS)
13.16
TTM Avg
-5.51
3Y Avg
-7.89
5Y Avg
-8.28
Market Cap
$13.11B
Earnings Per Share (EPS)
-3.58
TTM Avg
-3.33
3Y Avg
-3.49
5Y Avg
-3.66
Market Cap
$13.01B
Earnings Per Share (EPS)
3.35
TTM Avg
3.07
3Y Avg
2.44
5Y Avg
2.26
Market Cap
$14.54B
Earnings Per Share (EPS)
14.63
TTM Avg
1.61
3Y Avg
1.55
5Y Avg
0.83
Market Cap
$12.93B
Earnings Per Share (EPS)
0.42
TTM Avg
1.15
3Y Avg
1.07
5Y Avg
1.03
Market Cap
$14.63B
Earnings Per Share (EPS)
6.82
TTM Avg
4.10
3Y Avg
3.09
5Y Avg
2.95
Market Cap
$14.66B
Earnings Per Share (EPS)
3.19
TTM Avg
2.34
3Y Avg
1.78
5Y Avg
1.33
Market Cap
$14.69B
Earnings Per Share (EPS)
-4.85
TTM Avg
-1.35
3Y Avg
4.03
5Y Avg
5.21
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | $13.74B | N/A | -0.84 | -0.70 | -0.68 |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | 13.16 | -5.51 | -7.89 | -8.28 |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | -3.58 | -3.33 | -3.49 | -3.66 |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 3.35 | 3.07 | 2.44 | 2.26 |
| Jazz Pharmaceuticals plc (JAZZ)vs › | $14.54B | 14.63 | 1.61 | 1.55 | 0.83 |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 0.42 | 1.15 | 1.07 | 1.03 |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 6.82 | 4.10 | 3.09 | 2.95 |
| Exelixis, Inc. (EXEL)vs › | $14.66B | 3.19 | 2.34 | 1.78 | 1.33 |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | -4.85 | -1.35 | 4.03 | 5.21 |
| Tempus AI, Inc. (TEM)vs › | $12.56B | -1.44 | -3.00 | -2.43 | -2.16 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.44 |
| 2024-12-31 | -0.25 |
| 2023-12-31 | -0.78 |
| 2022-12-31 | -0.34 |
| 2021-12-31 | -0.71 |
| 2020-12-31 | -0.55 |
| 2019-12-31 | -0.97 |
| 2019-01-31 | 0.14 |
| 2018-01-31 | -0.44 |
| 2017-01-31 | -0.44 |
| 2016-01-31 | -0.48 |
| 2015-01-31 | -0.44 |
| 2014-01-31 | -0.49 |
| 2013-01-31 | -0.43 |
| 2012-01-31 | -0.47 |
| 2011-01-31 | -0.30 |
| 2010-01-31 | -0.21 |
| 2009-01-31 | -0.87 |
| 2008-01-31 | -0.83 |
| 2007-01-31 | -0.31 |
| 2006-01-31 | -0.11 |
| 2005-01-31 | -0.01 |
| 2004-01-31 | 0.00 |
